BioGaia’s preliminary results for the third quarter did not reach market expectations
(Figures in the brackets refer to the same period the previous year)During the third quarter of 2024, BioGaia will record a non-cash impairment of SEK 51.2 million, relating to the acquisition of MetaboGen AB. The impairment loss is mainly caused by a clinical study that did not meet its primary endpoints which resulted in updated assumptions of the impairment model. The study aimed to prove the efficacy of a next-generation probiotic product for individuals with metabolic syndrome. For the third quarter, sales are preliminarily estimated at SEK 304 million (318), a decrease of 4%.